EMAIL THIS PAGE TO A FRIEND

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Putative biomarker for phospholipid accumulation in cultured cells treated with phospholipidosis-inducing drugs: alteration of the phosphatidylinositol composition detected using high-performance liquid chromatography-tandem mass spectrometry.


PMID 25086420

Abstract

We developed a high-performance liquid chromatography-tandem mass spectrometric method for phospholipid biomarker discovery and applied it to a cell-based assay system for the screening of phospholipidosis-inducing drugs. We studied the compositions of phospholipid molecules exceeding 100 species in cultured cells and found a characteristic alteration in the composition by treatment with cationic amphiphilic drugs possessing phospholipidosis-inducing potency. The compositions of phosphatidylinositol in RAW264 cells were significantly affected by the drug treatment. Similar alterations were also found in THP-1 cells. These phenomena were not observed when cells were treated with warfarin, which does not have phospholipidosis-inducing potency. Structural analysis of the altered phosphatidylinositols by a product ion scan revealed the presence of certain fatty acyl chains. Based on our findings, we proposed a prediction parameter (PP) for phospholipid accumulation calculated from the relative compositions of phosphatidylinositol species. As the dosage of imipramine (a cationic amphiphilic drug) increased, both the PP and cellular phospholipid content increased. Our results suggest that PP has potency as a biomarker for phospholipid accumulation in cells treated with drugs.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A4571
3-(α-Acetonylbenzyl)-4-hydroxycoumarin sodium salt, ≥98%
C19H15NaO4
C1900000
Chlorpromazine hydrochloride, European Pharmacopoeia (EP) Reference Standard
C17H19ClN2S · HCl
1125006
Chlorpromazine hydrochloride, United States Pharmacopeia (USP) Reference Standard
C17H19ClN2S · HCl
31679
Chlorpromazine hydrochloride, VETRANAL, analytical standard
C17H19ClN2S · HCl
Y0000893
Imipramine for system suitability, European Pharmacopoeia (EP) Reference Standard
C19H24N2 · HCl
I0899
Imipramine hydrochloride, BioXtra, ≥99% (TLC)
C19H24N2 · HCl
I0100000
Imipramine hydrochloride, European Pharmacopoeia (EP) Reference Standard
C19H24N2 · HCl
1338007
Imipramine hydrochloride, United States Pharmacopeia (USP) Reference Standard
C19H24N2 · HCl
I7379
Imipramine hydrochloride, ≥99% (TLC)
C19H24N2 · HCl
I-902
Imipramine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material
C19H24N2 · HCl
T0014000
Tamoxifen citrate, European Pharmacopoeia (EP) Reference Standard
C26H29NO · C6H8O7
T0015000
Tamoxifen citrate for performance test, European Pharmacopoeia (EP) Reference Standard
C26H29NO · C6H8O7
T9262
Tamoxifen citrate salt, ≥99%
C26H29NO · C6H8O7
W0100000
Warfarin sodium, European Pharmacopoeia (EP) Reference Standard
C19H15NaO4
PHR1435
Warfarin Sodium
C19H15NaO4